世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
アンチセンス＆RNAi治療薬の市場規模、シェア、動向分析レポート：技術別（RNA干渉、アンチセンスRNA）、用途別（眼疾患、遺伝子疾患）、投与経路別、地域別、およびセグメント別予測、2024年～2030年Antisense & RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular Disorder, Genetic Disorder), By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030 アンチセンスとRNAi治療薬市場の成長と動向 Grand View Research, Inc.の最新レポートによると、アンチセンス＆RNAi治療薬の世界市場規模は、2024年から2030年にかけて18.12%のCAGRを記録し、2030年までに146... もっと見る
1～３営業日 
サマリーアンチセンスとRNAi治療薬市場の成長と動向Grand View Research, Inc.の最新レポートによると、アンチセンス＆RNAi治療薬の世界市場規模は、2024年から2030年にかけて18.12%のCAGRを記録し、2030年までに146億6000万米ドルに達すると予測されている。生物学的ベクターやナノテクノロジーの開発、新規薬剤分子の上市を含む臨床研究に対する資金援助の増加は、製品開発において重要であり、市場拡大の原動力となっている。 多国籍医療機関は、様々な疾患に対する新規治療法の開発に対する認識を高め、支援を行っている。民間の研究機関や企業は、研究機関を支援することで臨床試験の実施に参加しており、この分野の拡大を大きく後押しすると予測される。例えば、2022年3月、Biogen Inc.とIonis Pharmaceuticals, Inc.は、筋萎縮性側索硬化症（ALS）患者を治療するための治験用アンチセンス・オリゴヌクレオチドの第1相試験の結果を発表した。業界関係者によるこのような臨床試験の増加は、アンチセンスやRNAi療法に基づく製品の発売を増加させることにより、市場の成長を促進すると予想されている。 アンチセンス療法やRNAi療法は、細胞の成長サイクルに影響を与え、核酸を標的とする様々な疾患の治療に使用することができる。miRNAが遺伝子発現を再生し、タンパク質産生を制御する能力は、結果的に産業の進歩に影響を与え、大きな注目を集めている。米国科学振興協会が2023年7月に発表した論文によると、UMass Chan医科大学とRUSH大学医療センターが開発したアンチセンス療法が、脆弱X症候群の患者から採取した細胞標本でFMRPというタンパク質の産生を回復させるのに有用であることが判明した。業界におけるこのような進歩は、予測期間中、多くの疾患を治療するためのRNAiおよびアンチセンス治療薬の需要を促進すると予想される。 アンチセンス＆RNAi治療薬市場レポートハイライト - アンチセンスRNA技術は、神経変性疾患や遺伝性疾患などの疾患への幅広い応用により、技術分野で2023年に最大の売上シェアを占めた。 - RNA干渉分野は技術分野で最も急成長が見込まれる。この技術はさらにsiRNAとmiRNAに区分される。miRNAは細胞の同一性の維持に重要な役割を果たすため、癌の広がりをよりよく理解するために採用されている。 - アプリケーションに基づくと、遺伝性疾患セグメントの優位性は、新規遺伝性疾患治療法の開発に主要プレーヤーがますます注力していることに起因している。 - 世界のアンチセンスおよびRNAi治療薬市場では、北米が最大の売上シェアを占めている。同地域の優位性は、同地域に複数のプレーヤーが存在し、業界における地位を強化しようと努力していることに起因する。 - 欧州は、Secarnaのような主要企業が同地域で事業を展開し、拡大していることから、2024年から2030年までの予測期間で最も速い成長を記録すると予測されている。 目次Table of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Segment Definitions 1.2.1. Technology 1.2.2. Route of Administration 1.2.3. Application 1.2.4. Regional scope 1.2.5. Estimates and forecasts timeline. 1.3. Research Methodology 1.4. Information Procurement 1.4.1. Purchased database 1.4.2. GVR’s internal database 1.4.3. Secondary sources 1.4.4. Primary research 1.4.5. Details of primary research 1.5. Information or Data Analysis 1.5.1. Data analysis models 1.6. Market Formulation & Validation 1.7. Model Details 1.7.1. Commodity flow analysis (Model 1) 1.7.2. Approach 1: Commodity flow approach 1.7.3. Volume price analysis (Model 2) 1.7.4. Approach 2: Volume price analysis 1.8. List of Secondary Sources 1.9. List of Primary Sources 1.10. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Technology outlook 2.2.2. Route of Administration outlook 2.2.3. Application outlook 2.2.4. Regional outlook 2.3. Competitive Insights Chapter 3. Antisense & RNAi Therapeutics Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Market Dynamics 3.2.1. Market driver analysis 3.2.1.1. Presence of strong pipeline product portfolio 3.2.1.2. Introduction of technological advancements in drug delivery 3.2.1.3. Implementation of favorable government initiatives & external funding for R&D exercises 3.2.1.4. Rising collaborations between pharmaceutical companies 3.2.2. Market restraint analysis 3.2.2.1. Expensive and tedious research programs 3.2.2.2. Delivery of RNAi therapeutics and off-target effects 3.3. Antisense & RNAi Therapeutics Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.2. PESTEL Analysis Chapter 4. Antisense & RNAi Therapeutics Market: Technology Estimates & Trend Analysis 4.1. Technology Market Share, 2023 & 2030 4.2. Segment Dashboard 4.3. Global Antisense & RNAi Therapeutics Market by Technology Outlook 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 4.4.1. RNA Interference 4.4.1.1. RNA Interference Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2. Antisense RNA 4.4.2.1. Antisense RNA Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 5. Antisense & RNAi Therapeutics Market: Application Estimates & Trend Analysis 5.1. Application Market Share, 2023 & 2030 5.2. Segment Dashboard 5.3. Global Antisense & RNAi Therapeutics Market by Application Outlook 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 5.4.1. Ocular 5.4.1.1. Ocular Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.2. Cardio metabolic & Renal Disorders 5.4.2.1. Cardio metabolic & Renal Disorders Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.3. Respiratory Disorders 5.4.3.1. Respiratory Disorders Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.4. Cancer 5.4.4.1. Cancer Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.5. Neurodegenerative Disorders 5.4.5.1. Neurodegenerative Disorders Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.6. Genetic Disorders 5.4.6.1. Genetic Disorders Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.7. Infectious Diseases 5.4.7.1. Infectious Diseases Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.8. Skin Diseases 5.4.8.1. Skin Diseases Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.9. Others 5.4.9.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 6. Antisense & RNAi Therapeutics Market: Route of Administration Estimates & Trend Analysis 6.1. Route of Administration Market Share, 2023 & 2030 6.2. Segment Dashboard 6.3. Global Antisense & RNAi Therapeutics Market, by Route of Administration Outlook 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 6.4.1. Intravenous Injections 6.4.1.1. Intravenous Injections Market estimates and forecasts, 2018 to 2030 (USD million) 6.4.2. Intrathecal Injections 6.4.2.1. Intrathecal Injections Market estimates and forecasts, 2018 to 2030 (USD Million) 6.4.3. Subcutaneous Injections 6.4.3.1. Subcutaneous Injections Market estimates and forecasts, 2018 to 2030 (USD Million) 6.4.4. Others 6.4.4.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 7. Antisense & RNAi Therapeutics Market: Regional Estimates & Trend Analysis 7.1. Regional Market Share Analysis, 2023 & 2030 7.2. Regional Market Dashboard 7.3. Global Regional Market Snapshot 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030: 7.5. North America 7.5.1. U.S. 7.5.1.1. Key country dynamics 7.5.1.2. Target disease prevalence 7.5.1.3. Regulatory framework 7.5.1.4. Competitive scenario 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million) 7.5.2. Canada 7.5.2.1. Key country dynamics 7.5.2.2. Target disease prevalence 7.5.2.3. Regulatory framework 7.5.2.4. Competitive scenario 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million) 7.6. Europe 7.6.1. UK 7.6.1.1. Key country dynamics 7.6.1.2. Target disease prevalence 7.6.1.3. Regulatory framework 7.6.1.4. Competitive scenario 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.2. Germany 7.6.2.1. Key country dynamics 7.6.2.2. Target disease prevalence 7.6.2.3. Regulatory framework 7.6.2.4. Competitive scenario 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.3. France 7.6.3.1. Key country dynamics 7.6.3.2. Target disease prevalence 7.6.3.3. Regulatory framework 7.6.3.4. Competitive scenario 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.4. Italy 7.6.4.1. Key country dynamics 7.6.4.2. Target disease prevalence 7.6.4.3. Regulatory framework 7.6.4.4. Competitive scenario 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.5. Spain 7.6.5.1. Key country dynamics 7.6.5.2. Target disease prevalence 7.6.5.3. Regulatory framework 7.6.5.4. Competitive scenario 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.6. Norway 7.6.6.1. Key country dynamics 7.6.6.2. Target disease prevalence 7.6.6.3. Regulatory framework 7.6.6.4. Competitive scenario 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.7. Sweden 7.6.7.1. Key country dynamics 7.6.7.2. Target disease prevalence 7.6.7.3. Regulatory framework 7.6.7.4. Competitive scenario 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.8. Denmark 7.6.8.1. Key country dynamics 7.6.8.2. Target disease prevalence 7.6.8.3. Regulatory framework 7.6.8.4. Competitive scenario 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million) 7.7. Asia Pacific 7.7.1. Japan 7.7.1.1. Key country dynamics 7.7.1.2. Target disease prevalence 7.7.1.3. Regulatory framework 7.7.1.4. Competitive scenario 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million) 7.7.2. China 7.7.2.1. Key country dynamics 7.7.2.2. Target disease prevalence 7.7.2.3. Regulatory framework 7.7.2.4. Competitive scenario 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million) 7.7.3. India 7.7.3.1. Key country dynamics 7.7.3.2. Target disease prevalence 7.7.3.3. Regulatory framework 7.7.3.4. Competitive scenario 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million) 7.7.4. Australia 7.7.4.1. Key country dynamics 7.7.4.2. Target disease prevalence 7.7.4.3. Regulatory framework 7.7.4.4. Competitive scenario 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million) 7.7.5. South Korea 7.7.5.1. Key country dynamics 7.7.5.2. Target disease prevalence 7.7.5.3. Regulatory framework 7.7.5.4. Competitive scenario 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million) 7.7.6. Thailand 7.7.6.1. Key country dynamics 7.7.6.2. Target disease prevalence 7.7.6.3. Regulatory framework 7.7.6.4. Competitive scenario 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million) 7.8. Latin America 7.8.1. Brazil 7.8.1.1. Key country dynamics 7.8.1.2. Target disease prevalence 7.8.1.3. Regulatory framework 7.8.1.4. Competitive scenario 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million) 7.8.2. Mexico 7.8.2.1. Key country dynamics 7.8.2.2. Target disease prevalence 7.8.2.3. Regulatory framework 7.8.2.4. Competitive scenario 7.8.2.5. Mexico market estimates and forecasts, 2018 to 2030 (USD Million) 7.8.3. Argentina 7.8.3.1. Key country dynamics 7.8.3.2. Target disease prevalence 7.8.3.3. Regulatory framework 7.8.3.4. Competitive scenario 7.8.3.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million) 7.9. MEA 7.9.1. South Africa 7.9.1.1. Key country dynamics 7.9.1.2. Target disease prevalence 7.9.1.3. Regulatory framework 7.9.1.4. Competitive scenario 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million) 7.9.2. Saudi Arabia 7.9.2.1. Key country dynamics 7.9.2.2. Target disease prevalence 7.9.2.3. Regulatory framework 7.9.2.4. Competitive scenario 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million) 7.9.3. UAE 7.9.3.1. Key country dynamics 7.9.3.2. Target disease prevalence 7.9.3.3. Regulatory framework 7.9.3.4. Competitive scenario 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million) 7.9.4. Kuwait 7.9.4.1. Key country dynamics 7.9.4.2. Target disease prevalence 7.9.4.3. Regulatory framework 7.9.4.4. Competitive scenario 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Recent Developments & Impact Analysis, By Key Market Participants 8.2. Company/Competition Categorization 8.3. Vendor Landscape 8.3.1. List of key distributors and channel partners 8.3.2. Key customers 8.3.3. Key company market share analysis, 2023 8.3.4. Olix Pharmaceuticals 8.3.4.1. Company overview 8.3.4.2. Financial performance 8.3.4.3. Product benchmarking 8.3.4.4. Strategic initiatives 8.3.5. GSK plc 8.3.5.1. Company overview 8.3.5.2. Financial performance 8.3.5.3. Product benchmarking 8.3.5.4. Strategic initiatives 8.3.6. Sanofi 8.3.6.1. Company overview 8.3.6.2. Financial performance 8.3.6.3. Product benchmarking 8.3.6.4. Strategic initiatives 8.3.7. Alnylam Pharmaceuticals, Inc. 8.3.7.1. Company overview 8.3.7.2. Financial performance 8.3.7.3. Product benchmarking 8.3.7.4. Strategic initiatives 8.3.8. Ionis Pharmaceuticals, Inc. 8.3.8.1. Company overview 8.3.8.2. Financial performance 8.3.8.3. Product benchmarking 8.3.8.4. Strategic initiatives 8.3.9. Benitec Biopharma Inc 8.3.9.1. Company overview 8.3.9.2. Financial performance 8.3.9.3. Product benchmarking 8.3.9.4. Strategic initiatives 8.3.10. Silence Therapeutics 8.3.10.1. Company overview 8.3.10.2. Financial performance 8.3.10.3. Product benchmarking 8.3.10.4. Strategic initiatives 8.3.11. Arbutus Biopharma 8.3.11.1. Company overview 8.3.11.2. Financial performance 8.3.11.3. Product benchmarking 8.3.11.4. Strategic initiatives 8.3.12. Bio-Path Holdings Inc 8.3.12.1. Company overview 8.3.12.2. Financial performance 8.3.12.3. Product benchmarking 8.3.12.4. Strategic initiatives 8.3.13. Antisense Therapeutics Limited. 8.3.13.1. Company overview 8.3.13.2. Financial performance 8.3.13.3. Product benchmarking 8.3.13.4. Strategic initiatives
SummaryAntisense & RNAi Therapeutics Market Growth & Trends Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Segment Definitions 1.2.1. Technology 1.2.2. Route of Administration 1.2.3. Application 1.2.4. Regional scope 1.2.5. Estimates and forecasts timeline. 1.3. Research Methodology 1.4. Information Procurement 1.4.1. Purchased database 1.4.2. GVR’s internal database 1.4.3. Secondary sources 1.4.4. Primary research 1.4.5. Details of primary research 1.5. Information or Data Analysis 1.5.1. Data analysis models 1.6. Market Formulation & Validation 1.7. Model Details 1.7.1. Commodity flow analysis (Model 1) 1.7.2. Approach 1: Commodity flow approach 1.7.3. Volume price analysis (Model 2) 1.7.4. Approach 2: Volume price analysis 1.8. List of Secondary Sources 1.9. List of Primary Sources 1.10. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.2.1. Technology outlook 2.2.2. Route of Administration outlook 2.2.3. Application outlook 2.2.4. Regional outlook 2.3. Competitive Insights Chapter 3. Antisense & RNAi Therapeutics Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook 3.2. Market Dynamics 3.2.1. Market driver analysis 3.2.1.1. Presence of strong pipeline product portfolio 3.2.1.2. Introduction of technological advancements in drug delivery 3.2.1.3. Implementation of favorable government initiatives & external funding for R&D exercises 3.2.1.4. Rising collaborations between pharmaceutical companies 3.2.2. Market restraint analysis 3.2.2.1. Expensive and tedious research programs 3.2.2.2. Delivery of RNAi therapeutics and off-target effects 3.3. Antisense & RNAi Therapeutics Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.2. PESTEL Analysis Chapter 4. Antisense & RNAi Therapeutics Market: Technology Estimates & Trend Analysis 4.1. Technology Market Share, 2023 & 2030 4.2. Segment Dashboard 4.3. Global Antisense & RNAi Therapeutics Market by Technology Outlook 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 4.4.1. RNA Interference 4.4.1.1. RNA Interference Market estimates and forecasts 2018 to 2030 (USD Million) 4.4.2. Antisense RNA 4.4.2.1. Antisense RNA Market estimates and forecasts 2018 to 2030 (USD Million) Chapter 5. Antisense & RNAi Therapeutics Market: Application Estimates & Trend Analysis 5.1. Application Market Share, 2023 & 2030 5.2. Segment Dashboard 5.3. Global Antisense & RNAi Therapeutics Market by Application Outlook 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 5.4.1. Ocular 5.4.1.1. Ocular Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.2. Cardio metabolic & Renal Disorders 5.4.2.1. Cardio metabolic & Renal Disorders Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.3. Respiratory Disorders 5.4.3.1. Respiratory Disorders Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.4. Cancer 5.4.4.1. Cancer Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.5. Neurodegenerative Disorders 5.4.5.1. Neurodegenerative Disorders Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.6. Genetic Disorders 5.4.6.1. Genetic Disorders Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.7. Infectious Diseases 5.4.7.1. Infectious Diseases Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.8. Skin Diseases 5.4.8.1. Skin Diseases Market estimates and forecasts, 2018 to 2030 (USD Million) 5.4.9. Others 5.4.9.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 6. Antisense & RNAi Therapeutics Market: Route of Administration Estimates & Trend Analysis 6.1. Route of Administration Market Share, 2023 & 2030 6.2. Segment Dashboard 6.3. Global Antisense & RNAi Therapeutics Market, by Route of Administration Outlook 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following 6.4.1. Intravenous Injections 6.4.1.1. Intravenous Injections Market estimates and forecasts, 2018 to 2030 (USD million) 6.4.2. Intrathecal Injections 6.4.2.1. Intrathecal Injections Market estimates and forecasts, 2018 to 2030 (USD Million) 6.4.3. Subcutaneous Injections 6.4.3.1. Subcutaneous Injections Market estimates and forecasts, 2018 to 2030 (USD Million) 6.4.4. Others 6.4.4.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 7. Antisense & RNAi Therapeutics Market: Regional Estimates & Trend Analysis 7.1. Regional Market Share Analysis, 2023 & 2030 7.2. Regional Market Dashboard 7.3. Global Regional Market Snapshot 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030: 7.5. North America 7.5.1. U.S. 7.5.1.1. Key country dynamics 7.5.1.2. Target disease prevalence 7.5.1.3. Regulatory framework 7.5.1.4. Competitive scenario 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million) 7.5.2. Canada 7.5.2.1. Key country dynamics 7.5.2.2. Target disease prevalence 7.5.2.3. Regulatory framework 7.5.2.4. Competitive scenario 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million) 7.6. Europe 7.6.1. UK 7.6.1.1. Key country dynamics 7.6.1.2. Target disease prevalence 7.6.1.3. Regulatory framework 7.6.1.4. Competitive scenario 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.2. Germany 7.6.2.1. Key country dynamics 7.6.2.2. Target disease prevalence 7.6.2.3. Regulatory framework 7.6.2.4. Competitive scenario 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.3. France 7.6.3.1. Key country dynamics 7.6.3.2. Target disease prevalence 7.6.3.3. Regulatory framework 7.6.3.4. Competitive scenario 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.4. Italy 7.6.4.1. Key country dynamics 7.6.4.2. Target disease prevalence 7.6.4.3. Regulatory framework 7.6.4.4. Competitive scenario 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.5. Spain 7.6.5.1. Key country dynamics 7.6.5.2. Target disease prevalence 7.6.5.3. Regulatory framework 7.6.5.4. Competitive scenario 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.6. Norway 7.6.6.1. Key country dynamics 7.6.6.2. Target disease prevalence 7.6.6.3. Regulatory framework 7.6.6.4. Competitive scenario 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.7. Sweden 7.6.7.1. Key country dynamics 7.6.7.2. Target disease prevalence 7.6.7.3. Regulatory framework 7.6.7.4. Competitive scenario 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million) 7.6.8. Denmark 7.6.8.1. Key country dynamics 7.6.8.2. Target disease prevalence 7.6.8.3. Regulatory framework 7.6.8.4. Competitive scenario 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million) 7.7. Asia Pacific 7.7.1. Japan 7.7.1.1. Key country dynamics 7.7.1.2. Target disease prevalence 7.7.1.3. Regulatory framework 7.7.1.4. Competitive scenario 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million) 7.7.2. China 7.7.2.1. Key country dynamics 7.7.2.2. Target disease prevalence 7.7.2.3. Regulatory framework 7.7.2.4. Competitive scenario 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million) 7.7.3. India 7.7.3.1. Key country dynamics 7.7.3.2. Target disease prevalence 7.7.3.3. Regulatory framework 7.7.3.4. Competitive scenario 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million) 7.7.4. Australia 7.7.4.1. Key country dynamics 7.7.4.2. Target disease prevalence 7.7.4.3. Regulatory framework 7.7.4.4. Competitive scenario 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million) 7.7.5. South Korea 7.7.5.1. Key country dynamics 7.7.5.2. Target disease prevalence 7.7.5.3. Regulatory framework 7.7.5.4. Competitive scenario 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million) 7.7.6. Thailand 7.7.6.1. Key country dynamics 7.7.6.2. Target disease prevalence 7.7.6.3. Regulatory framework 7.7.6.4. Competitive scenario 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million) 7.8. Latin America 7.8.1. Brazil 7.8.1.1. Key country dynamics 7.8.1.2. Target disease prevalence 7.8.1.3. Regulatory framework 7.8.1.4. Competitive scenario 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million) 7.8.2. Mexico 7.8.2.1. Key country dynamics 7.8.2.2. Target disease prevalence 7.8.2.3. Regulatory framework 7.8.2.4. Competitive scenario 7.8.2.5. Mexico market estimates and forecasts, 2018 to 2030 (USD Million) 7.8.3. Argentina 7.8.3.1. Key country dynamics 7.8.3.2. Target disease prevalence 7.8.3.3. Regulatory framework 7.8.3.4. Competitive scenario 7.8.3.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million) 7.9. MEA 7.9.1. South Africa 7.9.1.1. Key country dynamics 7.9.1.2. Target disease prevalence 7.9.1.3. Regulatory framework 7.9.1.4. Competitive scenario 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million) 7.9.2. Saudi Arabia 7.9.2.1. Key country dynamics 7.9.2.2. Target disease prevalence 7.9.2.3. Regulatory framework 7.9.2.4. Competitive scenario 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million) 7.9.3. UAE 7.9.3.1. Key country dynamics 7.9.3.2. Target disease prevalence 7.9.3.3. Regulatory framework 7.9.3.4. Competitive scenario 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million) 7.9.4. Kuwait 7.9.4.1. Key country dynamics 7.9.4.2. Target disease prevalence 7.9.4.3. Regulatory framework 7.9.4.4. Competitive scenario 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million) Chapter 8. Competitive Landscape 8.1. Recent Developments & Impact Analysis, By Key Market Participants 8.2. Company/Competition Categorization 8.3. Vendor Landscape 8.3.1. List of key distributors and channel partners 8.3.2. Key customers 8.3.3. Key company market share analysis, 2023 8.3.4. Olix Pharmaceuticals 8.3.4.1. Company overview 8.3.4.2. Financial performance 8.3.4.3. Product benchmarking 8.3.4.4. Strategic initiatives 8.3.5. GSK plc 8.3.5.1. Company overview 8.3.5.2. Financial performance 8.3.5.3. Product benchmarking 8.3.5.4. Strategic initiatives 8.3.6. Sanofi 8.3.6.1. Company overview 8.3.6.2. Financial performance 8.3.6.3. Product benchmarking 8.3.6.4. Strategic initiatives 8.3.7. Alnylam Pharmaceuticals, Inc. 8.3.7.1. Company overview 8.3.7.2. Financial performance 8.3.7.3. Product benchmarking 8.3.7.4. Strategic initiatives 8.3.8. Ionis Pharmaceuticals, Inc. 8.3.8.1. Company overview 8.3.8.2. Financial performance 8.3.8.3. Product benchmarking 8.3.8.4. Strategic initiatives 8.3.9. Benitec Biopharma Inc 8.3.9.1. Company overview 8.3.9.2. Financial performance 8.3.9.3. Product benchmarking 8.3.9.4. Strategic initiatives 8.3.10. Silence Therapeutics 8.3.10.1. Company overview 8.3.10.2. Financial performance 8.3.10.3. Product benchmarking 8.3.10.4. Strategic initiatives 8.3.11. Arbutus Biopharma 8.3.11.1. Company overview 8.3.11.2. Financial performance 8.3.11.3. Product benchmarking 8.3.11.4. Strategic initiatives 8.3.12. Bio-Path Holdings Inc 8.3.12.1. Company overview 8.3.12.2. Financial performance 8.3.12.3. Product benchmarking 8.3.12.4. Strategic initiatives 8.3.13. Antisense Therapeutics Limited. 8.3.13.1. Company overview 8.3.13.2. Financial performance 8.3.13.3. Product benchmarking 8.3.13.4. Strategic initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
Grand View Research社の医薬品分野での最新刊レポート
本レポートと同じKEY WORD（rnai therapeutics）の最新刊レポートよくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ（Grand View Research）は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |
